Nonetheless, it should be pointed out that this study included only type 1 diabetic patients on insulin therapy between 13 and 39 years of age, and, as was mentioned earlier, the greatest risks of hypoglycemia and cognitive deficit would be present in children who presented with the disease at less than 5 years of age [77–80]. The gene discussed is INS; the disease is Hypoglycemia.